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Like other HIV-1 auxiliary proteins, Vpr is conserved within all the human (HIV-1, HIV-2)
and simian (SIV) immunodeficiency viruses. However, Vpr and homologous HIV-2, and
SIV Vpx are the only viral auxiliary proteins specifically incorporated into virus particles
through direct interaction with the Gag precursor, indicating that this presence in the core
of the mature virions is mainly required for optimal establishment of the early steps of the
virus life cycle in the newly infected cell. In spite of its small size, a plethora of effects
and functions have been attributed to Vpr, including induction of cell cycle arrest and
apoptosis, modulation of the fidelity of reverse transcription, nuclear import of viral DNA in
macrophages and other non-dividing cells, and transcriptional modulation of viral and host
cell genes. Even if some more recent studies identified a few cellular targets that HIV-1
Vpr may utilize in order to perform its different tasks, the real role and functions of Vpr
during the course of natural infection are still enigmatic. In this review, we will summarize
the main reported functions of HIV-1 Vpr and their significance in the context of the viral
life cycle.
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INTRODUCTION
The vpr gene is conserved among human (HIV-1 and HIV-2) and
simian immunodeficiency viruses (SIV) and encodes the regu-
latory viral protein R (Vpr), a small basic protein (14 kDa) of
96 amino acids (Ogawa et al., 1989; Hattori et al., 1990; Steffy
and Wong-Staal, 1991; Tristem et al., 1992). The importance of
Vpr has been initially shown in macaque rhesus monkeys that
were experimentally infected with a vpr-mutated SIVmac, and
exhibited a decrease in virus replication and a delay in disease
development progression (Lang et al., 1993; Hoch et al., 1995).
In vitro, in the absence of Vpr, HIV-1 replicates less efficiently in
macrophages, a cell type that represents an important viral reser-
voir by harboring the virus over long periods of time (Connor
et al., 1995). Despite its small size, HIV-1 Vpr has been shown
to have several roles during the viral life cycle. Due to its spe-
cific incorporation into the viral particle by interaction with the
Pr55Gag-derived p6 protein, Vpr is readily present upon entry of
the virus into the cell, which speaks in favor for enrollment dur-
ing early steps of viral replication (see Figure 1). In this regard,
Vpr has been shown to influence the reverse transcription of
HIV-1 via the interaction and recruitment of the human uracil
DNA glycosylase 2, an enzyme of the DNA repair machinery
(Guenzel et al., 2012). A relationship that is not without contro-
versy since different research reports argue whether UNG2 might
rather have a negative impact or even no impact on HIV-1 repli-
cation (Schrofelbauer et al., 2005; Kaiser and Emerman, 2006;
Yang et al., 2007). Furthermore, Vpr also affects the nuclear
import of the viral DNA within the pre-integration complex
(PIC), the cell cycle progression, the regulation of apoptosis
and the transactivation of the HIV-1 LTR as well as host cell
genes.
This review will be focused on the Vpr protein of HIV-1 and
will give a summary of the multifunctional nature of Vpr during
the viral life cycle in order to integrate previous and more recent
studies.
THE STRUCTURE OF Vpr
HIV-1 Vpr is a relatively small protein composed of 96 amino acid
residues (Figure 2A) (Checroune et al., 1995; Ramboarina et al.,
2004; Kamiyama et al., 2013). The secondary and higher-order
structures of Vpr have been investigated by nuclear magnetic res-
onance (NMR), circular dichroism (CD), and fluorescence spec-
troscopy (Zhao et al., 1994; Wang et al., 1996; Mahalingam et al.,
1997; Kichler et al., 2000; Bruns et al., 2003; Morellet et al., 2003;
Kamiyama et al., 2013). According to NMR studies on the full-
length Vpr protein dissolved in acidic aqueous-organic solvents
(Figure 2B) (Morellet et al., 2003), the central region of the Vpr
polypeptide chain folds into three amphiphilic helices (Sherman
et al., 2002; Bruns et al., 2003; Kamiyama et al., 2013). These
bundled α-helices span residues 17–33, 38–50, and 55–77 and
are flanked by unstructured flexible N- and C-terminal domains
that are negatively or positively charged, respectively (Morellet
et al., 2003). Four conserved proline residues at position 4, 10, 14,
and 35 which are subjected to cis/trans isomerization are found
in the N-terminal domain (reviewed in Bruns et al., 2003; Le
Rouzic and Benichou, 2005). It was indeed reported that the cel-
lular peptidyl-propyl isomerase cyclophilin A was able to interact
with Vpr via prolines (position 14 and 35) for correct folding
of the viral protein (Zander et al., 2003). The carboxy-terminal
domain of Vpr contains six arginine residues between positions
73 and 96 (see Figure 2A), and this domain shows similarity to
those of arginine-rich protein transduction domains. This might
potentially explain the transducing properties of Vpr and its abil-
ity to cross the cell membrane lipid bilayer (Kichler et al., 2000;
Sherman et al., 2002; Coeytaux et al., 2003). Additionally, the
third helix of Vpr is rich in leucine residues (Schüler et al., 1999),
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FIGURE 1 | Vpr functions and early steps of the HIV-1 life cycle.
Schematic view of the early steps of the HIV-1 infection of a target cell. The
functional events in which the Vpr protein is involved are highlighted. Vpr has
been shown to play multiple functions during the virus life cycle, including an
effect on the accuracy of the reverse-transcription process, the nuclear
import of the viral DNA as a component of the pre-integration complex, cell
cycle progression, regulation of apoptosis, and the transactivation of the
HIV-LTR as well as host cell genes.
where one side of the helix presents a stretch of hydrophobic
side chains that can form a leucine-zipper like motif (Figure 2).
This region was proposed to account for the formation of Vpr
oligomers (Wang et al., 1996; Mahalingam et al., 1997; Schüler
et al., 1999; Fritz et al., 2008) and for interaction with certain
cellular partners (reviewed in Planelles and Benichou, 2009).
Vpr has been shown to exist as dimers, trimers, tetramers and
higher order multimers (Zhao et al., 1994), however it is still not
completely elucidated how the dimeric or multimeric states of the
protein affect the different functions of Vpr. A real-time study
using a flow cytometry fluorescence resonance energy transfer has
confirmed that Vpr self-associates within live cells (Bolton and
Lenardo, 2007). Self-association was dependent on the hydropho-
bic patch that is located on the third α-helix and mutations
in this region did not impair the ability of Vpr to induce G2
arrest, suggesting that oligomerization of Vpr is not absolutely
required for the functions of the protein. In addition, muta-
tions in the arginine-rich domain, such as R80A and R87/88A,
did not impair self-association but were unable to induce G2
arrest (Bolton and Lenardo, 2007). Therefore, it appears that Vpr
does not require oligomerization toward induction of the cell
cycle blockage but the exposed hydrophobic amino acids in the
amino-terminal helix-1 are important for the cell cycle arrest
and cytopathogenic functions of Vpr (Barnitz et al., 2011). A
more recent study reports that oligomerization of Vpr is essen-
tial for incorporation into virus particles (Venkatachari et al.,
2010). Moreover, it has been recently proposed that Vpr may
assume an antiparallel helical dimer with the third α-helices of
the two subunits facing each other, and the His71 and Trp54
play a crucial role in this dimer formation (Kamiyama et al.,
2013).
Vpr IS INCORPORATED INTO VIRUS PARTICLES
Vpr is expressed at a late stage of the virus life cycle, but it is
present during the early steps of infection in target cells since it
is packaged into virions that were released from the producing
cells. The incorporation of Vpr occurs through a direct inter-
action with the carboxy-terminal p6 region of the gag-encoded
Pr55Gag precursor (Bachand et al., 1999; Paillart and Göttlinger,
1999; Selig et al., 1999; Jenkins et al., 2001a,b). The integrity of
the α-helices of Vpr is required for efficient packaging into viri-
ons (Singh et al., 2000), and a leucine-rich (LR) motif found in
the p6 region of the Pr55Gag precursor is directly involved in the
interaction with Vpr (Kondo and Göttlinger, 1996; Selig et al.,
1999; Jenkins et al., 2001a,b; Fritz et al., 2010). The Pr55Gag
p6 region has also been found to be phosphorylated during
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FIGURE 2 | Primary sequence and three-dimensional structure of the
HIV-1 Vpr protein. (A) Primary sequence of the Vpr protein from the
HIV-1Lai strain. The 3 α-helices are boxed in green. Domains and Leu
residues of Vpr involved in the nuclear import (black lines) and nuclear export
(Leu in red) of proteins are indicated. The Trp residue in position 54 as well as
the Gln residue critical for Vpr binding to UNG2 and DCAF1 are highlighted in
blue and purple, respectively. (B) Three-dimensional structure of the HIV-1
Vpr protein (adapted from Morellet et al., 2003). The three α-helices (17–33,
38–50, 55–77) are colored in green, respectively; the loops and flexible
domains are in blue.
HIV-1 infection by atypical protein kinase C (Hemonnot et al.,
2004) regulating the incorporation of Vpr into HIV-1 virions
and thereby supporting virus infectivity (Kudoh et al., 2014).
After assembly and proteolytic cleavage of Pr55Gag in matrix,
capsid, nucleocapsid (NCp7), and p6 mature proteins, Vpr is
recruited into the conical core of the virus particle (Accola et al.,
2000; Welker et al., 2000) where it is tightly associated with
the viral RNA (Zhang et al., 1998; De Rocquigny et al., 2000).
Interestingly, Vpr displays a higher avidity for NCp7 than for
the mature p6 protein (Dong et al., 1997; Selig et al., 1999;
Jenkins et al., 2001a,b). Since p6 is excluded from the virion
core (Accola et al., 2000; Welker et al., 2000), Vpr could switch
from the p6Gag region of the precursor to the mature NCp7
protein in order to gain access to the core of the infectious
virus particle budding at the cell surface. In any case, p6 has
been reported to show a high affinity for membrane bilayers
which substantially increases the interaction between p6 and Vpr
(Salgado et al., 2009). It was estimated that Vpr is efficiently
incorporated in HIV-1 virions with a Vpr/Pr55Gag ratio of ∼1:7
(Knight et al., 1987; Cohen et al., 1990; Welker et al., 2000),
which may represent 275 molecules of Vpr per virion. More
recently it has been shown that the HIV-1 Pr55Gag precursor
induces the recruitment of Vpr oligomers to the plasma mem-
brane (Fritz et al., 2010). Vpr oligomerization has been found to
be essential for binding of Vpr to Pr55Gag and for its accumu-
lation at the plasma membrane early during Pr55Gag assembly,
but the exact role of these oligomers is not certain yet (Fritz et al.,
2010).
The incorporation of Vpr has also been used as a unique tool
to target cargoes such as cellular and viral proteins or drugs into
viral particles (Wu et al., 1995; Yao et al., 1999; Fritz et al., 2010).
This property found extensive use in studies that evaluated the
respective functions of integrase (IN) and reverse transcriptase
(RT) during virus replication by expressing Vpr-IN and Vpr-RT
fusions in trans in virus-producing cells (Wu et al., 1997, 1999;
Liu et al., 1999). Furthermore, Vpr fused to the green fluorescence
protein (GFP) has been used to tag HIV particles in order to fol-
low intracellular virus behavior during the early intracellular steps
of infection in target cells (Loeb et al., 2002; Steffens and Hope,
2003; Fritz et al., 2010).
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Vpr AND THE CELL CYCLE
Among the range of functions of the Vpr protein, the
Vpr-dependent G2 arrest activity was extensively explored since
it was described for the first time in 1995 (He et al., 1995; Jowett
et al., 1995; Re et al., 1995; Rogel et al., 1995). The Vpr pro-
tein encapsided into HIV-1 virions is able to block proliferation
of newly infected T lymphocytes. Following infection, these cells
accumulate at the G2-M phase and show a 4N DNA content.
The first studies proposed that the presence of Vpr leads to the
accumulation of the hyperphosphorylated form of the cyclin-
dependent kinase CDC2 (the complex p34 cdc2/cyclin B). This
inactive form of the complex would be able to block the cell cycle
before the mitosis.
This cytostatic function of Vpr is well conserved among pri-
mate lentiviruses (Planelles et al., 1996; Stivahtis et al., 1997), and
could be a strategy used by HIV and SIV to improve viral repli-
cation and protein expression, and even to reactivate the virus
through an epigenetic control of the LTR promoter (Yao et al.,
1998; Thierry et al., 2004). The biological significance of this cell
cycle arrest during the natural infection is not well understood,
but the HIV-1 LTR seems to be more active in the G2 phase,
implying that the G2 arrest may confer a favorable cellular envi-
ronment for efficient transcription of HIV-1 (Goh et al., 1998). In
agreement, the Vpr-induced G2 arrest correlates with high level
of viral replication in primary human T cells. Overexpression
of dominant negative mutant of the p34 cdc2 kinase shows that
Vpr-induced G2 arrest correlates with HIV-1 activation (Goh
et al., 1998). Vpr might also be involved in virus activation
through other interactions such as the formation of a complex
with p53 and the transcription factors Sp1 (Wang et al., 1995;
Sawaya et al., 1998). This complex could lead to the activation
of the p21/WAF promoter resulting in the transactivation of the
viral LTR (Cui et al., 2006). Using a human hematopoietic stem
cell-transplanted humanized mouse model, it was recently shown
that Vpr causes G2 cell cycle arrest and apoptosis predominantly
in proliferating CCR5+ CD4+ T cells, which mainly consist of
regulatory CD4+ T cells (Tregs), resulting in Treg depletion and
enhanced virus production during acute infection in vivo (Sato
et al., 2013). In addition, recent results just published by Laguette
et al. (2014) show that the interaction of Vpr with the structure-
specific endonuclease (SSE) regulator SLX4 complex (SLX4com)
is crucial for the G2-arrest activity but also for escape of HIV-1
from innate immune sensing in infected cells.
Some studies try to correlate the Vpr structure with cell cycle
regulation. Historically, this function of Vpr was associated with
the helix-3 and the flexible C-terminal part of the protein (Marzio
et al., 1995; Mahalingam et al., 1997; Chen et al., 1999). Some
key phosphorylations of the C-terminus part have also been asso-
ciated with the G2 arrest, such as phosphorylation of the Ser79
residue (see Figure 2A) (Zhou and Ratner, 2000). Vpr is mainly
localized in the nucleus and at the nuclear envelope where pre-
vious reports indicated it could induce herniations and burstings
of the nuclear membrane and even defects in the nuclear lamina
(de Noronha et al., 2001; Sörgel et al., 2012). These morpho-
logical modifications could impact several nuclear factors and
redistribute a large range of proteins from the nucleus to the cyto-
plasm leading to alteration of the cell cycle. Indeed, the cyclins
involved in the cell cycle regulation are closely regulated and their
spatio-temporal distribution is primordial for the continuity of
the cell cycle. More recently, interactions between Vpr and chro-
matin have been reported (Belzile et al., 2010; Shimura et al.,
2011). Vpr can cause epigenetic disruption of heterochromatin
by inducing the displacement of heterochromatin protein 1-α
(HP1-α) through acetylation of the histone H3 and causes prema-
ture chromatids separation and consequently G2 arrest (Shimura
et al., 2011). The interaction between Vpr and the chromatin
should target and activate the ataxia telangiectasia mutated and
Rad3-related kinases ATM/ATR, two of the main sensors of the
cell cycle (Koundrioukoff et al., 2004). The link between ATR and
the Vpr-dependent G2 arrest was initially reported by Roshal et al.
(Roshal et al., 2003) (for review on ATR pathway, see Sørensen
and Syljuåsen, 2012). The ATR and ATM proteins control the
G2 arrest provoked by DNA damage but it is controversial if Vpr
really causes DNA damage or just mimics this damage and acti-
vates some sensors involved in this process (Cliby et al., 2002).
It was reported that the inhibition of ATR abrogates the Vpr-
dependent G2 arrest. Following ATR activation by Vpr, Chk1
is activated through phosphorylation and required for the G2
arrest (Li et al., 2010). Clearly, Vpr acts on the cell cycle by a
cascade of reversible phosphorylations. The expression of Vpr
correlates with inactivation of the p34/cdc2 CDK1 kinase asso-
ciated with cyclin B. Cdc2 is normally activated by the cdc5
phosphatase which is inactive in its hypophosphorylated form
in Vpr-expressing cells (He et al., 1995; Re et al., 1995), whereas
Wee1 inhibits the cdc2 kinases (Sørensen and Syljuåsen, 2012).
Vpr seems to be able to directly activate the Wee1 protein by
binding to its “N” lobe but this interaction is not sufficient for
induction of the G2 arrest (Kamata et al., 2008). However, other
key regulators of the cell cycle interacting with Vpr could be
members of the 14-3-3 protein family (Kino et al., 2005) which
bind phosphorylated serine/threonine proteins such as the cell
cycle regulators Wee1, Cdc25, and Chk1. Consequently, 14-3-3
could regulate activities and distribution of these proteins (Lopez-
Girona et al., 1999; Hermeking and Benzinger, 2006). These
authors revealed that overexpression of 14-3-3 leads to an increase
of the cell cycle arrest in the presence of Vpr while the absence of
this scaffolding protein reduces the Vpr-induced activity. Another
study revealed how Vpr disrupts 14-3-3θ from centrosome and
increases its association with the importin β, Cyclin B1, and Cdk1
(Bolton et al., 2008).
Today, almost all the new studies about the Vpr-induced G2
arrest try to identify the potential target of Vpr degraded by
the proteasome machinery. Indeed, several groups clearly showed
that Vpr connects the DCAF1 adaptor of the Cul4A ubiquitin
ligase to a so far unidentified host target protein linked to the
G2 arrest (Belzile et al., 2007; DeHart et al., 2007; Le Rouzic
et al., 2007; Schrofelbauer et al., 2007). First, the interactions
between Vpr and cullins 1 and 4 (Cul1, Cul4), belonging to the
ubiquitin ligase complex, were reported (Schrofelbauer et al.,
2007). Then, the Vpr-binding protein (VprBP) was described
as a substrate specificity module in Cul4 and DDB1 (damaged-
DNA specific binding protein 1)-based ubiquitine ligase E3
complexes (Angers et al., 2006; He et al., 2006; Higa et al.,
2006a; Jin et al., 2006). Furthermore, other teams described a
Frontiers in Microbiology | Virology March 2014 | Volume 5 | Article 127 | 4
Guenzel et al. HIV-1 Vpr protein
larger complex where Vpr was associated with Cul4A, DDB1,
Rbx2/Roc1 and an ubiquitin-conjugating enzyme or E2. At the
same time VprBP was renamed DDB1-and Cul4-associated fac-
tor (DCAF)-1 (Belzile et al., 2007; DeHart et al., 2007; Hrecka
et al., 2007; Le Rouzic et al., 2007; Schrofelbauer et al., 2007;
Tan et al., 2007; Wen et al., 2007). The Cul4-DDB1-E3 ligase
complex can bind several DCAFs and seems involved in the
maintenance and control of the genome stability, DNA replica-
tion and cell cycle check point control (Sugasawa et al., 2005;
Higa et al., 2006b; Wang et al., 2006). From these studies, a
model where Vpr binds the Cul4-DDB1-DCAF1 E3 ligase to
trigger the degradation of a putative protein responsible for the
G2 arrest has emerged (Dehart and Planelles, 2008). In this
model, Vpr uses two distinct interfaces for binding, one for
the attachment to VprBP/DCAF1 and the other for the puta-
tive substrate protein. Vpr binds DCAF1 through the LR motif
found between amino acids 60 and 68 while the C-terminal
basic flexible region binds to the substrate to be ubiquitinylated
and degraded and responsible for G2 arrest (Zhao et al., 1994;
DeHart et al., 2007; Le Rouzic et al., 2007). Recently, Belzile et al.
(2010) proposed that Vpr is present in the nucleus and more
specifically inside nuclear foci where it is associated with VprBP
and the DDB1-CUL4A-E3 ubiquitine ligase. These foci colocal-
ize with DNA repair foci containing proteins such as γH2AX
and RPA2. This association may lead to the recruitment and the
degradation of a chromatin-bound substrate via a K48-linked
polyubiquitinylation (Belzile et al., 2010) which activates the key
protein ATR and the G2 arrest. Finally, a new essential actor of
the Vpr-dependent G2 arrest, the SSE regulator SLX4com has
been recently identified by proteomic analysis (Laguette et al.,
2014). Vpr activates SLX4com through direct interaction with
SLX4 leading to the recruitment of VprBP and the kinase-active
PLK1. This association would lead to the cleavage of DNA by
SLX4-associated MUS81-EME1 endonucleases. Vpr activation of
premature MUS81-EME1 induces accumulation of FANCD2 foci
and consequently DNA intermediates cleavage and replication
stress.
Vpr AND APOPTOSIS
Acute phase of AIDS is characterized by a net decrease of CD4+ T
cells, and the hallmark of the chronic phase is a gradual decrease
of the peripheral CD4+ T cells. While the virus mainly targets
lymphocytes and macrophages, no depletion of macrophages has
been reported and these terminally-differentiated cells may rather
serve as virus reservoirs. The reason why infected macrophages
were not susceptible to apoptosis has been recently explored.
Using macrophage-like cells derived from differentiated THP1
CD4+ myeloid cells, a recent report showed that Vpr is not able
to downregulate the anti-apoptotic protein cIAP1/2 (Busca et al.,
2012). However, Mishra et al. (2007) previously revealed the pos-
sibility that the C-terminal part of Vpr could induce apoptosis in
monocytes via a JNK-dependant pathway.
Although different HIV-1-induced pathways for apoptosis
induction have been described, Vpr appears as one of the
main actors of the cell death observed during HIV-1 infec-
tion. However, it is still controversial how Vpr induces apoptosis
and/or necrosis. Moreover, uninfected bystander T cells can be
also targeted by Vpr, since Vpr can get access to the extra-
cellular compartment like a soluble protein (Reiss et al., 1990;
Cummins and Badley, 2010; Abbas, 2013). A previous model
for Vpr-induced apoptosis proposed that Vpr would be able to
bind the WxxF motif of the transmembrane adenine nucleotide
transporter (ANT) protein exposed in the inner membrane of
mitochondria. Jacotot et al. (2000, 2001) were the first to detect
this interaction and found that Vpr could also bind to another
member of the permeability transition pore complex (PTPC), the
voltage-dependent anion channel (VDAC). This team showed the
capacity of a synthetic Vpr polypeptide to trigger permeabiliza-
tion of the mitochondrial membrane resulting in the collapse of
the mitochondrial transmembrane potential. Following perme-
abilization of both inner and outer mitochondrial membranes
(Ghiotto et al., 2010), the release of pro-apoptotic proteins like
the cytochrome c forms the apoptosome with the caspase 9
and Apaf-1 and allows recruitment of caspase 3. Bax, another
pore forming complex protein should also be involved in the
Vpr-induced cell death since a conformational change and acti-
vation of Bax was detected in apoptotic cells expressing Vpr
(Andersen et al., 2006). In this study, the authors character-
ized cell death in mice, and described that ANT may promote a
necrotic cell death rather than apoptosis.
It was indeed discussed whether the Vpr-induced G2 arrest
was linked to the observed apoptosis in Vpr expressing cells.
Earlier, some studies concluded that Vpr-induced apoptosis was
independent of the G2 arrest activity (Nishizawa et al., 2000a,b)
showing that a C-terminal truncated form of Vpr still induced
apoptosis but did not induce G2 arrest. However, others andmore
recent studies found a correlation between both Vpr activities
and suggested that apoptosis was a consequence of the prolonged
G2 arrest (Andersen et al., 2006). According to Stewart and col-
leagues, apoptosis would happen in cells after the G2 arrest as a
consequence of the blockage, and this was observed in human
fibroblasts, T cell lines, as well as primary peripheral blood lym-
phocytes (Stewart et al., 1997, 1999). Accordingly, Zhu et al.
(2001) showed that treating cells with caffeine, an inhibitor of
both ATM and ATR, which are key proteins involved in cell cycle
control, abrogated both G2 arrest and apoptosis. Trying to under-
stand this ATR-dependent mechanism, subsequent studies from
the same team described an activation of the DNA repair enzyme
BRCA1 leading to the regulation of the growth arrest and DNA
damage protein 45α (GADD45α) involved in the cell death pro-
cess (Zimmerman et al., 2004; Andersen et al., 2005). Moreover,
some cell cycle regulators such as Wee1 and Chk1 could also
be involved in the Vpr-dependent apoptosis pathway. The Vpr-
dependent phosphorylation of Chk1, an event that begins during
S phase of the cell cycle, could also trigger apoptosis (Li et al.,
2010).
Furthermore, it was reported that Vpr may impact the
immune system homeostasis by stimulating the secretion of TNF-
α by dendritic cells, resulting in apoptosis of CD8+ T cells
(Majumder et al., 2007). Vpr could also increase expression of the
NKG2D stress ligand in CD4+ T cells promoting their destruc-
tion by the Natural Killer (NK) cells (Ward et al., 2009; Richard
et al., 2010). According to Ward et al. (2009), this mechanism
causes a link between the G2 arrest and the apoptosis since
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they showed NKG2D expression is dependent of ATR activation
by Vpr.
Finally, some studies revealed that 40–50% of HIV-1 seroposi-
tive patients have neurocognitive disorders (Ances and Ellis, 2007;
Jones et al., 2007; Harezlak et al., 2011), and different theo-
ries have been proposed to explain these neurological disorders.
Among the Vpr effects, some hypothesized that extracellular Vpr
might be able to enter into neurons (Rom et al., 2009) where it
can cause apoptosis. Jones et al. (2007) tested the effect of soluble
Vpr in neurons and detected apoptosis involving cytochrome c
release, p53 induction, and activation of caspase-9. This study also
suggested that Vpr triggers the release of the inflammatory IL-6
cytokine by astrocytes which could affect neuron survival. More
recently, it was shown that Vpr could also act on the glycolytic
pathway of astrocytes leading to secretion of stress molecules
(Ferrucci et al., 2013).
Vpr AND THE REVERSE TRANSCRIPTION
After virus entry, the viral core is released into the cytoplasm of
the target cell where the reverse transcription of the viral RNA
takes place within a large nucleoprotein complex (Farnet and
Haseltine, 1991; Bukrinsky et al., 1993; Miller et al., 1997; Fassati
and Goff, 2001; Nermut and Fassati, 2003; Lyonnais et al., 2013).
This reverse transcription complex (RTC) contains the two copies
of viral RNA and the viral RT, IN, NCp7, Vpr and a fewmolecules
of the matrix protein. It is generally believed that the reverse tran-
scription process is initiated in virus particles and then completed
in the cytoplasm after the virus has entered into the target cell
(Figure 1). The reverse transcription process is likely to take place
in parallel during both virus uncoating and trafficking through
the cytoplasm (for reviews, see Goff, 2001; and Pomerantz, 2000).
Several studies confirmed that Vpr co-localizes with the viral
nucleic acids and IN within purified HIV-1 RTCs (Fassati et al.,
2003; Nermut and Fassati, 2003; Steffens and Hope, 2003), and
remains associated with the viral DNA within 4–16 h after infec-
tion (Fassati and Goff, 2001). Interestingly, Vpr has recently been
reported to be essential for unintegrated HIV-1 gene expression
and de-novo virus production in a virus replication pathway uti-
lizing RT DNA products that failed to integrate (Poon and Chen,
2003; Trinité et al., 2013).
In addition to a potential role in the initiation step of the
reverse transcription process (Stark and Hay, 1998), it has been
shown that Vpr modulated the in vivo mutation rate of HIV-
1 by influencing the accuracy of the reverse transcription. The
HIV-1 RT is an error-prone RNA-dependent DNA polymerase,
and quantification of the in vivo rate of forward virus muta-
tions per replication cycle revealed that the mutation rate was
4-fold higher in the absence of Vpr expression when measured
in dividing cells using a genetically engineered system (Mansky
and Yemin, 1995; Mansky, 1996). Furthermore, analysis in non-
dividing cells showed that this phenotype is even more pro-
nounced in primary monocyte-derived macrophages (MDMs)
leading to a 16-fold increase of the HIV-1 mutation frequency
(Chen et al., 2004). Strikingly, this activity correlates with the
interaction of Vpr with the nuclear form of uracil DNA glycosy-
lase (UNG2) (Mansky et al., 2000), an enzyme of the base excision
repair system that specifically removes the RNA base uracil from
DNA. The inclusion of uracil in DNA can occur either by mis-
incorporation of dUTP or by cytosine deamination. While the
Trp residue in position 54 located in the exposed loop connecting
the second and the third α-helix of HIV-1 Vpr has been shown
to be critical to maintain the interaction with UNG2, the Vpr-
binding site was mapped within the C-terminal part of UNG2,
and occurs through a WxxF motif. So far, three distinct cellu-
lar partners of Vpr were known to contain a WxxF motif: the
TFIIB transcription factor, the adenosine-nucleotide translocator
(ANT) and UNG2 (as reviewed in Planelles and Benichou, 2009).
However, the WxxF motif is not sufficient for Vpr binding, since
other cellular Vpr-interacting proteins, such as DCAF1 or DICER
for example, still bind to Vpr independently of the presence of a
WxxF motif within their primary sequence (Belzile et al., 2007;
DeHart et al., 2007; Le Rouzic et al., 2007; Schrofelbauer et al.,
2007; Casey Klockow et al., 2013).
Some authors suggested that the association of Vpr with
UNG2 in virus-producing cells allows the incorporation of a
catalytically active enzyme into HIV-1 particles where UNG2
may directly influence the reverse transcription accuracy (Mansky
et al., 2000; Chen et al., 2004), and this plays a specific role in
the modulation of the virus mutation rate. The model support-
ing the direct contribution of incorporated UNG2 in the reverse
transcription process was demonstrated by using an experimental
system in which UNG2 was recruited into virions independently
of Vpr. UNG2 was expressed as a chimeric protein fused to the
C-terminal extremity of the VprW54R mutant, a Vpr variant
that fails to recruit UNG2 into virions and to influence the virus
mutation rate, even though it is incorporated as efficiently as
the wild-type Vpr protein. The VprW54R-UNG2 fusion is also
efficiently packaged into HIV-1 virions and can restore a muta-
tion rate equivalent to that observed with wild-type Vpr, both
in actively dividing cells and in MDMs. In agreement with this
phenotype on the virus mutation frequency, it was finally docu-
mented that the Vpr-mediated incorporation of UNG2 into virus
particles contributed to the ability of HIV-1 to replicate in pri-
mary macrophages. When the VprW54R variant was introduced
into an infectious HIV-1 molecular clone, virus replication in
macrophages was both reduced and delayed. Although it was pro-
posed that the viral integrase was also able to mediate interaction
with UNG2 (Priet et al., 2003), Vpr seems to be the main viral
determinant that allows for the incorporation of UNG2 into virus
particles. However, further analyses are required to document the
nature of interactions between UNG2, Vpr, IN as well as RT both
in virus-producing cells and in target cells.
Other studies also confirmed that UNG2 was efficiently
recruited into virus particles (Priet et al., 2005; Kaiser and
Emerman, 2006; Yang et al., 2007; Jones et al., 2010), indicat-
ing that this recruitment might influence the accuracy of the
reverse transcription process and has a positive influence on viral
replication (Chen et al., 2004; Priet et al., 2005; Jones et al.,
2010). Interestingly, it has been recently reported that HIV-1
DNA generated in infected macrophages and CD4-positive T
cells is heavily uracilated (Yan et al., 2011). However, the spe-
cific role of UNG2 incorporation into virions was challenged by
other studies (Schrofelbauer et al., 2005; Kaiser and Emerman,
2006; Yang et al., 2007). While the specificity of the interaction
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between Vpr and UNG2 was not questioned, these studies sug-
gested a detrimental (Schrofelbauer et al., 2005; Yang et al.,
2007; Eldin et al., 2013) or dispensable (Kaiser and Emerman,
2006) effect of UNG2 on virus replication. In the model sug-
gesting a detrimental effect on UNG2 on virus replication, Vpr
was shown to induce the proteasomal degradation of UNG2 in
virus-producing cells in order to prevent its recruitment into
virus particles (Schrofelbauer et al., 2005, 2007; Eldin et al.,
2013). It has also been reported that the Vpr-UNG2 interac-
tion temporarily impairs the uracil excision activity of UNG2
in infected cells (Eldin et al., 2013). However, other data have
indicated that the Vpr-induced reduction of endogenous UNG2
observed in HIV-1 infected cells was not solely related to pro-
teasomal degradation (Langevin et al., 2009; Nekorchuk et al.,
2013) and that UNG2 might not be responsible for the degra-
dation of HIV-1 DNA containing misincorporated dUTP which
prevents viral integration (Weil et al., 2013). More recently, it
has been argued that incorporation of UNG2 into HIV-1 parti-
cles may not be detrimental for virus infection in target cells but
rather has a positive impact on virus replication and virus infec-
tivity achieved through a non-enzymatic mechanism mapping
within a 60-amino-acid long domain located in the N-terminal
region of UNG2 (Guenzel et al., 2012). Interestingly, this domain
is also required for interaction of UNG2 with the p32 sub-
unit (RPA2) of the replication protein A complex (Nagelhus
et al., 1997; Otterlei et al., 1999; Mer et al., 2000; De Silva and
Moss, 2008). It was observed that enforced virion recruitment of
UNG2, through UNG2 overexpression in virus producing cells,
similarly influenced infectivity of X4 and R5 HIV-1 strains in
transformed cell lines and MDMs, respectively (Guenzel et al.,
2012), which stands in contrast to another report suggesting that
UNG2 was exclusively required for efficient infection of primary
cells by R5-tropic viruses (Jones et al., 2010). Strikingly, viruses
produced from cells depleted of endogenous UNG2 and RPA2
resulted in significantly reduced infectivity and replication, the
latter evidenced by a reduced amount of viral transcripts mea-
sured during the reverse transcription process (Guenzel et al.,
2012). These new intriguing findings are not yet completely
understood and further investigations are needed to clarify the
mechanism.
HIV-1 and other lentiviruses are unusual among retroviruses
in their ability to infect resting or terminally differentiated cells.
While Vpr has been shown to facilitate the nuclear import of
viral DNA in non-dividing cells (see below), the virion incor-
poration of UNG2 via Vpr may also contribute to the ability
of HIV-1 to replicate in primary macrophages. This implies
that UNG2 is a cellular factor that plays an important role in
the early steps of the HIV-1 replication cycle (i.e., viral DNA
synthesis). This observation is in agreement with a report show-
ing that the misincorporation of uracil into minus strand viral
DNA affects the initiation of the plus strand DNA synthesis
in vitro (Klarmann et al., 2003). This observation suggests that
UNG2 is likely to be recruited into HIV-1 particles to subse-
quently minimize the detrimental accumulation of uracil into
the newly synthesized proviral DNA. While further works are
needed to explain the precise mechanism for how the UNG2
catalytic activity may specifically influence HIV-1 replication in
macrophages, it is worth noting that non-dividing cells express
low levels of UNG and contain relatively high levels of dUTP
(Chen et al., 2002). Similarly, most non-primate lentiviruses,
such as feline immunodeficiency virus (FIV), caprine-arthritis-
encephalitis virus (CAEV) and equine infectious anemia virus
(EIAV), have also developed an efficient strategy to reduce accu-
mulation of uracil into viral DNA. These lentiviruses encode
and package a viral-encoded dUTP pyropshophatase (dUT-
Pase) into virus particles, an enzyme that hydrolyzed dUTP to
dUMP, and thus maintains a low level of dUTP. Interestingly,
replication of FIV, CAEV, or EIAV that lack functional dUT-
Pase activity is severely affected in non-dividing host cells
(e.g., primary macrophages). Taken together, these results indi-
cate that uracil misincorporation in viral DNA strands dur-
ing reverse transcription is deleterious for the ongoing steps
of the virus life cycle. The presence of a viral dUTPase or a
cellular UNG will prevent these detrimental effects for replica-
tion of non-primate and primate lentiviruses in macrophages,
respectively.
Finally, it is intriguing to note that two viral auxiliary pro-
teins from HIV-1, Vpr and Vif, can both influence the fidelity
of viral DNA synthesis. The Vif protein forms a complex with
the cellular deaminase APOBEC3G thereby preventing its encap-
sidation into virions (Sheehy et al., 2002; Lecossier et al., 2003;
Mangeat et al., 2003; Mariani et al., 2003; Stopak et al., 2003),
while Vpr binds the DNA repair enzyme UNG2. In this context
it was suggested that incorporation of UNG2 into viral parti-
cles would have a detrimental effect on reverse transcription by
introducing a basic sites into viral DNA in regards to uracil
residues resulting from cytosine deamination by the cytidine
deaminase APOBEC3G (Schrofelbauer et al., 2005; Yang et al.,
2007). While the specific role of UNG2 in the antiviral activ-
ity of APOBEC3G was not directly questioned (Schrofelbauer
et al., 2005), others reported data indicating that the antivi-
ral activity of overexpressed APOBEC3G was partially affected
when viruses were produced in UNG2-depleted 293T cells (Yang
et al., 2007). However, these data are in apparent contradiction
with results from other reports in which viruses were produced
in UNG2-depleted cells which expressed or did not express
APOBEC3G (Priet et al., 2005; Jones et al., 2010; Guenzel et al.,
2012), but also from reports showing that APOBEC3G-mediated
restriction of HIV-1 was independent of UNG2 (Kaiser and
Emerman, 2006; Langlois and Neuberger, 2008). More recently,
and in favor for a correlative positive impact of UNG2, it has
been shown that the detrimental hypermutation of Hepatitis B
virus DNA induced by either APOBEC3G or interferon treat-
ment was enhanced in a human hepatocyte cell lines when
UNG2 activity was inhibited (Kitamura et al., 2013; Liang et al.,
2013). Additional investigations are thus required to further
understand this apparent contradiction regarding the role of
UNG2 for the antiviral activity of APOBEC restriction fac-
tors. However, it is tempting to speculate that the action of
both viral proteins may influence the mutation rate during
the course of HIV-1 infection, and their balance may play a
key role during disease progression and antiretroviral treat-
ment susceptibility in infected individuals (Fourati et al., 2010,
2012).
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Vpr AND THE VIRAL DNA NUCLEAR IMPORT
Like other retroviruses, HIV-1 has the capacity to infect and inte-
grate its genomic DNA into dividing cells like T lymphocytes, but
lentiviruses are also remarkable by their capacity to infect non-
dividing cells, in contrast to onco-retroviruses which need the dis-
integration of the nuclear envelope to allow access of their genome
for integration in the host genome (Greber and Fassati, 2003).
Indeed, HIV-1 can infect terminally-differentiated macrophages
and produces new virions after integration of its DNA into the
cell genome. The Vpr protein has been described as a potential
enhancer of HIV-1 replication especially in macrophages whereas
it does not impact on virus replication in proliferating T cells
(Balliet et al., 1994; Connor et al., 1995; Eckstein et al., 2001).
In macrophages, the viral DNA needs to be transported into
the interphasic nucleus by an active mechanism (Vodicka et al.,
1998). After virus entry into the cell, the viral genome is reverse-
transcribed in full length viral double-strand DNA which is
associated with viral and host cell proteins into the so-called PIC.
Among the protein components of the PIC, four viral proteins
have been detected (e.g., the reverse-transcriptase and integrase
enzymes, the matrix protein and Vpr) (Heinzinger et al., 1994;
Jenkins et al., 1998; Eckstein et al., 2001; Le Rouzic et al., 2002;
Schang, 2003; Suzuki et al., 2009).
Despite the absence of a basic canonical or a M9-dependant
nuclear localization signal (NLS) in the protein sequence, Vpr
shows evident karyophilic properties (Gallay et al., 1996; Jenkins
et al., 1998; Depienne et al., 2000). Finally, Vpr seems to use a
non-classical pathway to be transferred in the nucleus through
direct binding to importin-α (Gallay et al., 1996; Nitahara-
Kasahara et al., 2007). However, it was largely shown that Vpr
is able to shuttle between the cytoplasm and the nuclear com-
partments and could play a potential role in transport of the
viral DNA (Jenkins et al., 2001a,b; Sherman et al., 2001, 2003; Le
Rouzic et al., 2002). By using a photobleaching strategy on living
cells, Le Rouzic and colleagues revealed that Vpr-GFP has shut-
tling properties (Le Rouzic et al., 2002). This activity was linked
to the distal LR region, a classical nuclear export signal (NES) rec-
ognized by the CRM1-dependent pathway (Sherman et al., 2001,
2003). This NES could be involved in the release of Vpr back into
the cytoplasm, making it available for virion packaging through
interaction with the Pr55Gag precursor (Jenkins et al., 2001a,b).
The role of Vpr within the PIC has been studied in living cells
through tracking of a GFP-tagged form of Vpr (McDonald et al.,
2002). These authors evidenced a tight association between the
PIC and the cytoplasmic microtubules, targeting the viral DNA
toward the nucleus. The PIC moves along the cytoskeletal micro-
tubule filaments using the dynein/dynactin complex as a motor,
leading to its accumulation in the perinuclear region close to the
centrosome. So far, it is not known if Vpr plays an active role in
the intracytoplasmic transport of the PIC; it may be only associ-
ated with the complex and play a role later for nuclear membrane
anchoring and translocation of the viral DNA into the nucleus
(for review, Le Rouzic and Benichou, 2005).
The nuclear envelope contains two concentric membranes
with nuclear pore complexes (NPC) consisting of aqueous chan-
nels which allow for selective transport between the cytoplasmic
and nuclear compartments. The NPC corresponds to a 125 MDa
structure consisting of 30 distinct nuclear pore proteins, named
nucleoporins (Nups) (Cronshaw et al., 2002). Most of these Nups
have filamentous structures containing FG or FxFG motif repeats
emanating from both sides of the NPC and able to dock trans-
port factors (Rout and Aitchison, 2001). It was initially reported
that Vpr was able to recognize these FG motifs in Nups such
as p54 and p58 leading to the docking of Vpr to the nuclear
membrane (Fouchier et al., 1998; Popov et al., 1998). Another
interaction with the human CG1 (hCG1) nucleoporin has been
described by Le Rouzic et al. (2002). However, Vpr associated with
the N-terminal region of hCG1 while the FG repeats of this Nup
were located in the C-terminal part of the protein. This interac-
tion results in Vpr accumulation at the nuclear envelope, which
is believed to be involved in active nuclear import of the PIC in
non-dividing cells, such as macrophages (Jacquot et al., 2007).
Through these interactions with components of NPC, Vpr may
be responsible for the first step of viral DNA import by targeting
the PIC to the nuclear pore complex while other components of
the PIC could trigger the next step of the nuclear translocation.
As mentioned above, it was also reported that Vpr can induce
herniations and the dissociation of lamina and nuclear enve-
lope which provoke a blend of nuclear and cytoplasmic proteins
(de Noronha et al., 2001). The exact mechanism inducing these
membrane perturbations is not understood, but some authors
hypothesize that the interaction of Vpr with the NPC proteins
could impact nuclear membrane stability. Consequently it may
also facilitate the entry of the PIC through a non-conventional
pathway (Segura-Totten and Wilson, 2001).
CONCLUSIONS AND FUTURE DIRECTIONS
Like other HIV-1 auxiliary proteins, Vpr is a small but multifunc-
tional protein which is potentially able to interact with plenty
of cellular partners. During the last two decades, several groups
looked for such partners but the importance of such interactions
often needs to be better documented to support their real impact
on HIV-1 propagation, immune and antiretroviral treatment eva-
sion and disease progression. While major efforts have been made
during the last years to better define the molecular mechanisms
and cellular targets of Vpr, additional works are needed for the
complete understanding of its wide range of activities in key pro-
cesses during the early steps of the viral life cycle (i.e., reverse
transcription, intra-cytoplasmic routing and nuclear import of
the viral DNA). However, precise characterization of Vpr inter-
actions leading to the proteasomal degradation of some host cell
factors is certainly the main challenge for a better understand-
ing of the Vpr contribution to the overall pathogenesis of HIV-1
infection.
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